Changes in insulin like growth factors, myostatin and vascular endothelial growth factor in rat musculus latissimus dorsi by poly-3-hydroxybutyrate implants.
The present study aimed at researching the synergistic effect between an ectopic bone substitute and surrounding muscle tissue. To describe this effect, changes of insulin like growth factors (IGF1, IGF2), myostatin (GDF8) and vascular endothelial growth factor (VEGF) mRNA content of 12 Wistar-King rats musculus latissimus dorsi with implanted poly-3-hydroxybutyrate (PHB) scaffold were examined after 6 and 12 weeks. At each time interval six rats were killed and implants and surrounding tissues prepared for genetic evaluation. Eight rats without any implants served as controls. RNA was extracted from homogenized muscle tissue and reverse transcribed. Changes in mRNA content were measured by Real-Time PCR using specific primers for IGF1, IGF2, GDF8 and VEGF. Comparing the level of VEGF mRNA in muscle after 6 and 12 weeks to the controls, we could assess a significant increase of VEGF gene expression (p<0.05) whereas the level of mRNA expression was higher after 6 than after 12 weeks of treatment. Expression of IGF1 gene was also significantly increased as compared to the controls over the observed period of time (p<0.05). In the case of the IGF2 gene, the expression was significantly elevated after 6 weeks (p<0.05), but not significantly increased after 12 weeks (p>0.05). We observed a significantly decreased GDF8 gene expression (p<0.05) both after retrieval of implants after 6 as well as after 12 weeks. Moreover, mRNA level of GDF8 after 6 and 12 weeks were comparable the same. Our results show that PHB implants in rat musculus latissimus dorsi interact with the surrounding muscle tissue. This interaction works itself on growth potential of the muscle.
Gredes
T
T
Department of Orthodontics, Preventive and Pediatric Dentistry, Ernst-Moritz-Arndt University, Greifswald, Germany.
Spassov
A
A
Mai
R
R
Mack
H
H
Loster
B W
BW
Mazurkiewicz-Janik
M
M
Kubein-Meesenburg
D
D
Fanghanel
J
J
Gedrange
T
T
D000222:Adaptation, Physiological / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D018786:Bone Substitutes / Q000494:pharmacology*; D006885:Hydroxybutyrates / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D055435:Myostatin / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D009999:Ossification, Heterotopic / Q000378:metabolism; D010012:Osteogenesis / Q000502:physiology; D011091:Polyesters / Q000494:pharmacology*; D000091402:Prohibitins; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D023822:Tissue Engineering; D054457:Tissue Scaffolds; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D000094122:Polyhydroxybutyrates
D018786:Bone Substitutes; D006885:Hydroxybutyrates; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D055435:Myostatin; D011091:Polyesters; D000091402:Prohibitins; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; C000717332:Phb protein, rat; C003182:poly-beta-hydroxybutyrate; D000094122:Polyhydroxybutyrates